A single oral dose of the 75 mg tablet can provide fast pain relief, return patients to normal function within an hour, and remain effective for up to 48 hours for many patients, the company said.
The company said 86% of patients treated with a single dose of the pill did not use a migraine rescue medication within 24 hours.
Also read: Zydus gets USFDA approval for generic Canasa
“We think there’s a value-add for payers and patients by not having to pay for two different drugs – one for acute and one for prevention”, Biohaven Chief Executive Officer Vlad Coric told Reuters.
Drug’s largest opportunity will be in the treatment of acute migraine, given the increasing size of that market and a less-competitive environment than what now exists in migraine prevention, Mizuho analyst Vamil Divan said in a note prior to the approval.